Table of contents
- Overview of the Levofloxacin trials
- Conditions being studied
- Who can participate
- Trial phases and study designs
- Main outcomes and endpoints
- What each key trial is trying to learn
- What these studies may mean for patients
Overview of the Levofloxacin trials
The trial data show Levofloxacin being studied in several interventional trials, which means researchers assign treatments and then compare results. These studies are not about the drug itself as a textbook topic; they focus on how Levofloxacin is used in real trial settings for different infections and patient groups.[1]
Most of the listed studies are Phase 3 trials, with some Phase 2 trials and one Phase 4 trial. The studies are mostly authorised, and one is completed.[1]
Conditions being studied
Levofloxacin appears in trials for a wide range of infections. These include uncomplicated acute appendicitis, community-acquired pneumonia, bacteremia (a bloodstream infection), prosthetic joint infection, infective endocarditis, ventilator-associated pneumonia, and diabetic foot osteomyelitis.[2][3]
Some studies also involve special situations, such as infection risk in people with asymptomatic bacteriuria before bladder injections, infections linked to implanted bone material after fractures, and febrile neutropenia in children with cancer.[4][5]
Who can participate
Participant groups differ by trial. Some studies focus on adults with a specific infection, such as appendicitis, pneumonia, or bloodstream infection, while others include children or young adults with cancer, or patients with neurologic conditions and bladder problems.[2][4]
Several trials require patients to have a clearly defined infection or a defined risk state, such as CT-scan confirmed appendicitis, hospital-treated pneumonia, prosthetic joint infection, or infection of osteosynthesis material after a long bone fracture. In other words, the studies are aimed at specific medical situations, not at all patients who take antibiotics.[2][6]
Trial phases and study designs
Most Levofloxacin trials in the source data are randomized, meaning patients are assigned to treatment groups by chance. Some are also double-blind or placebo-controlled, which helps reduce bias by keeping treatment assignment hidden or by comparing against a placebo.[3]
The studies include non-inferiority designs, which test whether Levofloxacin-based treatment is not meaningfully worse than the comparison treatment. Other trials compare shorter versus longer antibiotic courses, or oral treatment versus intravenous treatment.[1][6]
Main outcomes and endpoints
The primary outcome changes from one trial to another, but the common theme is treatment success. Some studies measure discharge without surgery, no recurrent appendicitis, survival without relapse, cure at a set day, or no need for more antibiotics.[2][7]
Other trials measure broader outcomes, such as days alive and out of hospital, 90-day mortality, 6-month mortality, quality of life, health economic costs, and quality-adjusted life years (QALYs), which combine length of life and health-related quality of life.[1][8]
What each key trial is trying to learn
APPAC III and APPAC II study uncomplicated acute appendicitis and look at whether antibiotic treatment can resolve the condition without surgery, with success measured soon after treatment or at one year.[2][7]
LANDCAP 1 and LANDCAP 2 study community-acquired pneumonia and test inhaled Levofloxacin against other approaches, including standard intravenous antibiotics or saline control, with outcomes such as lung function change and days alive and out of hospital.[3][8]
SHORTEN-2 studies bacteremia caused by Pseudomonas aeruginosa and asks whether a 7-day course is better than a 14-day course, using treatment duration and a DOOR/RADAR score. DOOR/RADAR is a ranking method that combines benefit and harm into one outcome.[4]
SAB 7 and SNAP study Staphylococcus aureus bacteremia and compare different antibiotic strategies, including shorter treatment length and multiple possible drugs, with outcomes such as 90-day survival and failure or relapse.[5][9]
RiCOTTA studies infected joint prostheses caused by staphylococci and asks whether targeted monotherapy is not inferior to combination treatment, with treatment success measured 15 months after surgery and antibiotic treatment.[6]
RIFREE studies staphylococcal prosthetic valve endocarditis and compares a rifampin-free regimen with a rifampin-containing regimen, using all-cause mortality at 6 months as the main endpoint.[10]
CAT-CAP studies hospitalized patients with moderately severe community-acquired pneumonia and tests whether stopping antibiotics when stability criteria are reached is not inferior to standard duration, with cure at day 15 as the main outcome.[11]
COTRIVAP studies ventilator-associated pneumonia in intensive care and measures vital status at day 28, while e-STOP 2 studies when antibiotics can be safely stopped in high-risk febrile neutropenic children with cancer, using uncomplicated resolution at 28 days.[12][13]
ANTIBIOBONTA studies whether a peri-operative antibiotic strategy is needed for people with asymptomatic bacteriuria who receive intravesical botulinum toxin A injections, and it measures symptomatic urinary tract infection within 6 weeks.[14]
LIBRETTO studies diabetic foot osteomyelitis and compares local antibiotic delivery with systemic antibiotic therapy, with healing or osteomyelitis resolution at 12 and 24 weeks as the main outcome.[15]
What these studies may mean for patients
These trials show that Levofloxacin is being tested in many different infection settings, not just one disease. The research is especially focused on whether it can help patients recover with fewer hospital days, shorter treatment, or simpler treatment plans.[1][8]
For patients, the most important point is that each study has its own rules, target group, and success measure. That means participation depends on the exact infection, the severity of illness, age, and other study criteria.[2][13]
